Oritavancin: A new opportunity for outpatient therapy of serious infections

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 3, 2012, Pages

  Tice, Alan ^a  

^a Infections Limited Hawaii   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAROLINE; DAPTOMYCIN; ORITAVANCIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL WALL; BACTERICIDAL ACTIVITY; CELL MEMBRANE PERMEABILITY; CLOSTRIDIUM DIFFICILE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG USE; HEALTH CARE COST; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OUTPATIENT CARE; OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY; PATIENT SATISFACTION; PHLEBITIS; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; REIMBURSEMENT; SERIOUS INFECTION; SINGLE DRUG DOSE; TELEMEDICINE; UNSPECIFIED SIDE EFFECT; VANCOMYCIN RESISTANT ENTEROCOCCUS; VASCULAR ACCESS; WORK RESUMPTION;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 84859092496     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir1047     Document Type: Article

References (38)

1. Rucker RW, Harrison GM. Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics 1974; 54:358-60.
2. Poretz DM. Evolution of outpatient parenteral antibiotic therapy. Infect Dis Clin North Am 1998; 12:827-34.
3. Rehm SJ, Weinstein AJ. Home intravenous antibiotic therapy: a team approach. Ann Intern Med 1983; 99:388-92.
4. Poretz DM, Eron LJ, Goldenberg RI, et al. Intravenous antibiotic therapy in an outpatient setting. JAMA 1982; 248:336-9.
5. Tice AD. An office model of outpatient parenteral antibiotic therapy. Rev Infect Dis 1991; 13(Suppl 2):S184-8.
6. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy; IDSA guidelines. Clin Infect Dis 2004; 38:1651-72.
7. Tice AD. Handbook of outpatient parenteral therapy for infectious diseases. 2nd ed. Tarrytown, NY: CRG Publishing, 2006.
8. Nolet BR. Patient selection in outpatient parenteral antimicrobial therapy. Infect Dis Clin North Am 1998; 12:835-47.
9. Rathore MH. The unique issues of outpatient parenteral antimicrobial therapy in children and adolescents. Clin Infect Dis 2010; 51(Suppl 2):S209-15. Review.
10. Sharma R, Loomis W, Brown RB. Impact of mandatory inpatient infectious disease consultation on outpatient parenteral antibiotic therapy. Am J Med Sci 2005; 330:60-4.
11. Roberts RR, Scott RD 2nd, Hota B, et al. Costs attributable to healthcare-acquired infection in hospitalized adults and a comparison of economic methods. Med Care 2010; 48:1026-35.
12. Anderson DJ, Kirkland KB, Kaye KS, et al. Underresourced hospital infection control and prevention programs: penny wise, poundfoolish? Infect Control Hosp Epidemiol 2007; 28:767-73.
13. Milliman Care Guidelines 11th edition. 2007. Available at: http://www.careguidelines.com/company/press/pr-050807.shtml. Accessed 27 January 2011.
14. Fine MJ, Medsger AR, Stone RA, et al. The hospital discharge decision for patients with community-acquired pneumonia. Arch Intern Med 1997; 157:47-56.
15. Hoffman-Terry ML, Fraimow HS, Fox TR, Swift BG, Wolf JE. Adverse effects of outpatient parenteral antibiotic therapy. Am J Med 1999; 106:44-9.
16. Rehm SJ, Longworth DL. Rates of adverse events associated with community-based parenteral anti-infective therapy. J Clin Outcomes Manage 2000; 7:23-8.
17. Graham DR, Keldermans MM, Klemm LW, Semenza NJ, Shafer ML. Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters. Am J Med 1991; 91:95-100.
18. Le J, San Agustin M, Hernandez EA, Tran TT, Adler-Shohet FC. Complications associated with outpatient parenteral antibiotic therapy in children. Clin Pediatr (Phila) 2010; 49:1038-43.
19. Tice AD, Nolet BR. Delivery models for outpatient parenteral antimicrobial therapy. Outpatient Parenteral Antimicrobial Therapy: Current Status. Scientific American Medicine Special Edition 1997; 7-11.
20. Rehm SJ. Outpatient intravenous antibiotic therapy for endocarditis. Infect Dis Clin North Am 1998; 12:879-901, vi.
21. Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003; 114:723-8.
22. Brown RB. Outpatient parenteral antibiotic therapy in the management of community-acquired lower respiratory infections. Infect Dis Clin North Am 1998; 12:921-33, vii.
23. Tice AD, Strait K, Ramey R, Hoaglund PA. Outpatient parenteral antimicrobial therapy for central nervous system infections. Clin Infect Dis 1999; 29:1394-9.
24. Nguyen HH. Hospitalist to home: outpatient parenteral antimicrobial therapy at an academic center. Clin Infect Dis 2010; 51(Suppl 2):S220-3. Review.
25. Bartlett JG. A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis 2011; 53(Suppl 1):S4-7.
26. Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2010; 51(Suppl 2):S183-97. Review.
27. Tice AD, Rehm SJ. Meeting the challenges of methicillin-resistant Staphylococcus aureus with outpatient parenteral antimicrobial therapy. Clin Infect Dis 2010; 51(Suppl 2):S171-5.
28. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29:1275-9. Review.
29. McKay GA, Beaulieu S, Arhin FF, et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009; 63: 1191-9.
30. Bouza E, Burillo A. Oritavancin: a novel lipoglycopeptide active against gram-positive pathogens including multiresistant strains. Int J Antimicrob Agents 2010; 36:401-7.
31. Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010; 70:859-86.
32. Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother 2009; 53:4422-8.
33. Hartman CS, Wasilewski MM, Bates BM. Oritavancin in the treatment of complicated skin and skin structure infections (cSSSI): combined results of two phase 3 multinational trials [abstract]. In: Abstracts and summaries of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Annual Meeting of the Infectious Diseases Society of America (IDSA) (Washington, DC). Arlington, VA: IDSA, 2008.
34. Moriarty S, Wasilewski M, Rosen AS, et al. Safety of oritavancin versus vancomycin for treatment of patients with complicated skin and skin structure infections (poster). In: Abstracts and summaries of the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (Helsinki, Finland). Basel, Switzerland: ECCMID, 2009.
35. Dunbar LM, Milata J, McClure T, Wasilewski MM. SIMPLIFI Study Group. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother 2011; 55:3476-84.
36. Eron L. Telemedicine: the future of outpatient therapy? Clin Infect Dis 2010; 51(Suppl 2):S224-30.
37. Tice AD. Documenting the value of OPAT: outcomes studies and patient registries. Can J Infect Dis 2000; 10(Suppl A):45A-8.
38. Nathwani D, Tice AD. Ambulatory antimicrobial use: the value of an outcomes registry. J Antimicrob Chemother 2002; 49:149-54.